+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants



Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants



Vaccine 17(7-8): 887-892



With the aim to determine if immunization with two different live recombinant viral vectors could lead to an enhancement of the cellular immune response to HIV-1 antigens, we have characterized the CD8+ T cell response elicited against the V3 loop epitope from HIV-1 env protein in Balb/c mice immunized with either: a recombinant influenza virus (Flu-Env) expressing the V3 loop epitope from HIV-1 strain IIIB, a vaccinia virus recombinant (VV-Env) expressing the complete HIV-1-IIIB env protein, or a combination of both. The CD8+ T cell response, measured by the ELISPOT assay, in animals primed with Flu-Env and boosted with VV-Env was 5 to 6 times higher than in animals inoculated with either Flu-Env or VV-Env alone. Similar results were obtained with recombinant viruses expressing the V3 loop epitope or the complete env protein, respectively, from the MN strain of HIV-1. Our results indicate that the use of two different live vectors for priming and boosting has a synergistic effect on the immune response against HIV-1, and could represent a novel vaccination strategy against AIDS.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010588677

Download citation: RISBibTeXText

PMID: 10067695

DOI: 10.1016/s0264-410x(98)00274-6


Related references

Enhanced cellular immune responses to SIV Gag by immunization with influenza and vaccinia virus recombinants. Vaccine 21(17-18): 2097-2106, 2003

Mechanism of immunity to influenza: maternal and passive neonatal protection following immunization of adult ferrets with a live vaccinia-influenza virus haemagglutinin recombinant but not with recombinants containing other influenza virus proteins. Journal of General Virology 70: 1523-1531, 1989

Effect of virulence on immunogenicity of single and double vaccinia virus recombinants expressing differently immunogenic antigens: antibody-response inhibition induced by immunization with a mixture of recombinants differing in virulence. Journal of General Virology 80: 2901-2908, 1999

Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models. Vaccine 18(7-8): 623-632, 1999

Cell-mediated immune responses to influenza virus antigens expressed by vaccinia virus recombinants. Microbial Pathogenesis 1(5): 443-452, 1986

Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune response. European Journal of Immunology 16(12): 1479-1487, 1986

Protective immune response against cutaneous leishmaniasis by prime/booster immunization regimens with vaccinia virus recombinants expressing Leishmania infantum p36/LACK and IL-12 in combination with purified p36. Microbes and Infection 3(9): 701-711, 2001

A comparison of immunization with plasmid DNA and vaccinia recombinants containing the nucleoprotein gene of influenza in MHC class I deficient mice. Journal of Cellular Biochemistry Supplement 0(19A): 314, 1995

Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. Cancer Research 63(22): 7942-7949, 2003

Vaccinia virus recombinants expression of vesicular stomatitis virus genes and protective immunization of mice and cattle. Science (Washington D C) 227(4685): 433-435, 1985

Immunization of chimpanzees against hiv 1 using pure recombinant antigens live vaccinia virus recombinants or a conventional inactivated virus vaccine. De-The, G (Ed ) Aids 89-90: News And Views on Research And Control Xii+294p Medsi/Mcgraw-Hill: Paris, France; New York, New York, Usa Illus Paper 207-210, 1989